Effects of Tafluprost on Ocular Blood Flow

Zhang, Xinyue; Zhou, Xiaoyu; Zhao, Yang; Yang, Xiang; Zhou, Dengming; Chen, Baihua; Duan, Xuanchu

doi:10.1007/s40123-022-00566-z

Cited by 5 publications

(3 citation statements)

References 58 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In normal-tension glaucoma (NTG) patients with mean baseline IOP in the low teens, latanoprost did not affect the OPP [135] but increased in NTG patients with IOP in the upper teens [136]. Tafluprost improved the ocular blood flow in experimental studies [35]. The effect of timolol on OPP is not clear.…”

Section: Ocular Blood Flowmentioning

confidence: 99%

A Narrative Review of Pharmacotherapy of Glaucoma

Virani,

Rewri

2024

Future Pharmacology

View full text Add to dashboard Cite

Progressive loss of retinal ganglionic cells (RGC) causes degeneration of optic nerve axons, which leads to blindness in glaucoma. Elevated intraocular pressure (IOP) is the most important, treatable risk factor. Currently, the management of glaucoma is centred on reducing the IOP, and drugs in the form of topical drops are the first line of management. Drugs reduce IOP either by suppressing aqueous humour secretion or improving the aqueous humour outflow. Newer drugs added during the past three decades to the armamentarium of glaucoma treatment have targeted the aqueous outflow. With an evolving understanding of the pathogenesis of glaucoma, the role of 24-h IOP control and other IOP-independent risk factors affecting ocular blood flow and RGC toxicity is also being actively studied in clinical and pre-clinical models of glaucoma. The role of available drugs in controlling IOP over 24 h is being evaluated. Improvement of ocular blood flow and neuroprotection are seen as potential drug targets for preventing the loss of RGC. In this article, we review the pharmacotherapy of glaucoma based on current therapeutic principles.

show abstract

Section: Ocular Blood Flowmentioning

confidence: 99%

A Narrative Review of Pharmacotherapy of Glaucoma

Virani,

Rewri

2024

Future Pharmacology

View full text Add to dashboard Cite

show abstract

“…As with other commonly used IOP-lowering agents, despite their satisfactory IOP control and safety profile, these compounds seem to only partially affect ocular blood flow with tafluprost being the most effective. 9 Furthermore, FP agonists seem to lack any direct meaningful activity on the inflammation sometimes observed in glaucomatous eyes and are not reported to have an effect on retina cell survival, as has been reported for other IOP-lowering agents, such as the alpha‑2 adrenergic agonist, brimonidine. 10 …”

Section: Introductionmentioning

confidence: 94%

NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina

Sgambellone,

Marri,

Villano

et al. 2023

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose The purpose of this study was to assess the retinal protective activity and ocular hemodynamics after NCX 470 (0.1%) compared to bimatoprost administered as the US Food and Drug Administration (FDA)-approved drug (Lumigan − 0.01% ophthalmic solution, LUM) and at an equimolar dose (0.072%, BIM) to that released by NCX 470. Methods Endothelin-1 (ET-1) induced ischemia/reperfusion injury model in rabbits was used. ET-1 was injected nearby the optic nerve head (ONH) twice/week for 6 weeks. Starting on week 3, the animals received vehicle (VEH), NCX 470, LUM, or BIM (30 µL/eye, twice daily, 6 days/week) until the end of ET-1 treatment. Intraocular pressure (IOP), ophthalmic artery resistive index (OA-RI), and electroretinogram (ERG) data were collected prior to dosing and at different time points postdosing. Reduced glutathione, 8-Hydroxy 2-deoxyguanosine, and Caspase-3 were determined in the retina of treated eyes. DNA fragmentation was determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining. Results ET-1 increased IOP (VEH IOP_Baseline = 20.5 ± 0.8 and VEH IOP_Week6 = 24.8 ± 0.3 mmHg) and OA-RI (VEH OA-RI_Baseline = 0.36 ± 0.02 and VEH OA-RI_Week6 = 0.55 ± 0.01) and reduced rod/cone responses over time. Oxidative stress, inflammation, and apoptotic markers increased in ET-1-treated eyes. NCX 470 prevented IOP (NCX 470 IOP_Week6 = 18.1 ± 0.6 mmHg) and OA-RI changes (NCX 470 OA-RI_Week6 = 0.33 ± 0.01) and restored ERG amplitude leaving unaltered the respective latency; these effects were only partially demonstrated by LUM or BIM. Additionally, NCX 470 reduced oxidative stress, inflammation, and apoptosis in the retinas of treated eyes. BIM and LUM were numerically less effective on these parameters. Conclusions NCX 470 repeated ocular dosing ameliorates ocular hemodynamics and retinal cell dysfunction caused by ischemia/reperfusion via nitric oxide- and bimatoprost-mediated mechanisms. Translational Relevance If confirmed in clinical setting our data may open new therapeutic opportunities to reduce visual field loss in glaucoma.

show abstract

“…In normaltension glaucoma (NTG) patients with mean baseline IOP in the low teens, latanoprost did not affect OPP [115] but increased in NTG patients with IOP in the upper teens [116]. Tafluprost improved ocular blood flow in experimental studies [117]. The effect of timolol on OPP is not clear.…”

Section: Ocular Blood Flowmentioning

confidence: 99%

An Update on Pharmacotherapy of Glaucoma

Virani¹,

Rewri²

2023

Preprint

View full text Add to dashboard Cite

Progressive loss of retinal ganglionic cells (RGC) causes blindness in glaucoma. Elevated intraocular pressure (IOP) is the most important, treatable risk factor. Currently, the management of glaucoma is centred at reducing the IOP, and drugs in the form of topical drops are the first line of management. Drugs reduce IOP either by suppressing aqueous humour secretion or improving the aqueous humour outflow. Newer drugs added during the past three decades to the armamentarium of glaucoma treatment have targeted the aqueous outflow. With an evolving understanding of the pathogenesis of glaucoma, the role of 24-hour IOP control and other IOP-independent risk factors affecting ocular blood flow and RGC toxicity is also recognised. The role of available drugs in controlling IOP over 24-hours is being evaluated. Improvement of ocular blood flow and neuroprotection are seen as potential drug targets in preventing the loss of RGC. In this article, we review the pharmacotherapy of glaucoma based on current therapeutic principles.

show abstract

Effects of Tafluprost on Ocular Blood Flow

Cited by 5 publications

References 58 publications

A Narrative Review of Pharmacotherapy of Glaucoma

A Narrative Review of Pharmacotherapy of Glaucoma

NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina

An Update on Pharmacotherapy of Glaucoma

Contact Info

Product

Resources

About